London-based Clarivate Plc is embedding agentic AI across its Cortellis portfolio to automate complex workflows for life sciences research. By shifting from static information delivery to active task execution, the company aims to compress weeks of manual data analysis into hours, targeting faster decision-making in drug development and safety assessment.
The expansion introduces AI-driven tools designed to handle discovery, risk evaluation, and market strategy. Within Cortellis Drug Discovery Intelligence, researchers can now utilize natural language queries to evaluate therapeutic landscapes and prioritize compound targets, bypassing traditional manual synthesis of scientific data.
Safety teams gain similar leverage through the OFF-X platform, which employs multi-agent intelligence to identify potential liabilities earlier in the development cycle. Additionally, Cortellis Competitive Intelligence now features automated workflows that allow business development departments to assess external growth opportunities and shifting market dynamics with increased speed.
Anne Lecocq, Senior Vice President of R&D at Clarivate, noted that the transition marks an evolution for the platform from a simple information repository into a connected ecosystem. By automating high-friction tasks, the company intends to allow human experts to focus exclusively on strategic R&D decisions rather than data gathering. This rollout reflects a broader industry push toward integrating proprietary datasets with autonomous agents to reduce the time-to-market for new pharmaceutical products.
Comments (0)
No comments yet. Be the first!